Implant Sciences Recommended for Registration to ISO 9001:2008 and 14001:2004 International Standards
WILMINGTON, Mass., May 12, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the Company has completed the final registration audits with a global certification body with international recognition and has been recommended for registration to ISO 9001:2008 and 14001:2004 standards. Certificates for both standards will be awarded to the Company.
ISO 9001 is a quality management standard, developed and published by the International Organization for Standardization (ISO), a worldwide federation of national standards bodies. ISO 14001 is an Environmental Management System (EMS) developed by ISO, promoting requirements that achieve and demonstrate sound environmental policies.
In receiving these recommendations, Implant Sciences has demonstrated that it has successfully met the customer, statutory, and regulatory requirements as defined in the ISO 9001 Quality Management System (QMS) and the Environmental Standards requirements of ISO 14001, ensuring compliance with local, federal and international legal and other requirements.
In 2013, Implant Sciences moved into its expanded, state-of-the-art 58,000 square foot manufacturing facility. The Company's explosives trace detection products manufactured at the facility have received certifications and approvals from numerous regulatory agencies including the U.S. Transportation and Security Administration, STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China.
"Meeting the requirements for these ISO certifications further validates our commitment to the highest quality manufacturing standards, while also being responsible for our environment. Our global customer base is well aware of the high-performance and quality of our products. As we receive our ISO 9001:2008 and ISO 14001:2004 registrations, our customers will also be assured of the quality practices we maintain as we manufacture our products in Massachusetts," stated Implant Sciences' President and CEO, Glenn D. Bolduc.
"Our team completed a several month long process that included a stringent audit of management practices and process reviews. We are pleased that we've met the requirements and expect to receive our registration certificate shortly," added Dr. Bill McGann, Implant Sciences' Chief Operating Officer.
ISO (International Organization for Standardization) is the world's largest developer of voluntary International Standards. International Standards give state of the art specifications for products, services and good practice, helping to make industry more efficient and effective. Developed through global consensus, they help to break down barriers to international trade.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company's QS-B220 has received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation